

Industry-Sponsored Satellite Sessions

Industry Sponsored Satellite Sessions are independently staged and accredited or non-accredited educational or product theater events. A gateway fee making them accessible to attendees is paid by the presenters.

WEDNESDAY October 12

PRODUCT THEATER 1: **Biogen: The Latest NURTURE Trial Data on Pediatric Patients**

Wednesday, October 12, 3:00 PM - 4:00 PM
Exhibit Hall A, Duke Energy Center

Speakers

Diana Castro, MD
Neurologist and Neuromuscular Physician
Founder of Neurology and Neuromuscular Care Center
Founder of Neurology Rare Disease Center
Denton, TX

Gyula Acsadi, MD, PhD
Pediatric Neurologist, Chief of Pediatric Neurology
Connecticut Children's Medical Center
Hartford, CT

THURSDAY October 13

PRODUCT THEATER 2: **A Treatment Option for Seizures Associated with CDKL5 Deficiency Disorder (CDD)**

Thursday, October 13, 7:00 AM - 8:00 AM
Room 206, Duke Energy Center

This presentation will review the data of a randomized, controlled trial that evaluated the efficacy and safety of an antiseizure treatment in patients with refractory epilepsy associated with CDKL5 deficiency disorder (CDD).

M. Scott Perry, MD
Head of Neurosciences
Director, Jane and John Justin Institute for Mind Health
Medical Director, Genetic Epilepsy Clinic
Cook Children's Medical Center

PRODUCT THEATER 3: **GENENTECH: EVRYSDI**

Thursday, October 13, 12:30 PM - 1:30 PM
Exhibit Hall A, Duke Energy Center

Join us at an interactive symposium about Evrysdi to explore community and expert perspectives

SATELLITE SEMINAR 1: **Practical Clinical Management of Lennox-Gastaut Syndrome**

Thursday, October 13, 2022
12:30 PM - 1:00 PM: On-site Check-in and Lunch
1:00 PM - 2:30 PM: Satellite CME Seminar
Rooms 200 & 205, 2nd Floor, Duke Energy Center

PRE-REGISTER AT www.millermeded.com/LGS
Pre-registration does not guarantee seating. On-site registration may be available, space permitting.

Program Overview

Lennox-Gastaut syndrome (LGS) is a debilitating developmental and epileptic encephalopathy (DEE) characterized by multiple seizure types, diffuse slow spike-and-wave complexes on encephalograms, and cognitive impairment. Most patients are treatment-refractory and have life-long disability. Drop seizures are hallmark features of LGS, most notably tonic seizures. However, most patients will develop between 3 and 5 seizure types which wax and wane during disease progression. Generalized tonic clonic seizures (GTCs) are commonly observed and, even though they can occur at any point during the syndrome manifestations, usually occur in later stages of LGS. In addition to being associated with bodily injury and hospitalizations, GTCs are a primary risk factor for SUDEP (sudden unexpected death in epilepsy). In addition, as in other DEEs, LGS patients are significantly affected by developmental delays and behavioral issues. In this seminar we will review LGS and its clinical diagnosis and management, with practical focus on rational therapy choices that optimize patient management and may affect long-term outcomes.

Learning Objectives

After completing this activity, the participant should be better able to:

- Review clinical features and diagnostic challenges associated with Lennox-Gastaut syndrome
- Discuss seizure end points in clinical trials of Lennox-Gastaut syndrome and how they translate into clinical practice
- Review secondary outcomes that are unique to Lennox-Gastaut syndrome management and reasonable expectations for patient care

Faculty

Katherine Nickels, MD (Program Chair)
Associate Professor of Neurology
Mayo Clinic
Rochester, Minnesota

M. Scott Perry, MD
Head of Neurosciences
Jane and John Justin Institute for Mind Health
Cook Children's Medical Center
Fort Worth, Texas

Joseph E. Sullivan, MD
Professor of Neurology and Pediatrics
University of California, San Francisco (UCSF)
Director
UCSF Benioff Children's Hospital
Pediatric Epilepsy Center of Excellence
San Francisco, California

CREDITS AVAILABLE

Physicians – maximum of 1.50 *AMA PRA Category 1 Credit(s)*[™]

Jointly provided by Postgraduate Institute for Medicine and Miller Medical Communications, LLC.

Grant Source: This live activity is supported by an independent educational grant from Zogenix, Inc.

SATELLITE SEMINAR 2: A Spotlight on the Management of AADC Deficiency: Experience With Investigational Intraputamine Gene Replacement Therapy

Thursday, October 13, 2022
5:30 PM – 7:00 PM
Rooms 200 & 205, 2nd Floor, Duke Energy Center

PRE-REGISTER AT: <https://cvent.me/gnaMbn>

Speakers

Jennifer O'Malley, MD, PhD
Stanford University School of Medicine

Sudhakar Vadivelu, DO
Cincinnati Children's Hospital

Richard Poulin & Judy Wei
Parents of a child with AADC deficiency

Grant Source: PTC Therapeutics

PRODUCT THEATER 4:

Alexion: Pediatric Cases of Neurofibromatosis Type 1 (NF1) With Symptomatic, Inoperable Plexiform Neurofibromas (PN)

Thursday, October 13, 6:00 PM – 7:00 PM
Exhibit Hall A, Duke Energy Center

Program Description

Alexion invites you to a branded presentation featuring 3 cases of pediatric patients with Neurofibromatosis Type 1 with symptomatic, inoperable Plexiform Neurofibromas (NF1 PN). The presentation will discuss patient diagnosis, treatment, and care.

Speaker

Audrey Green-Murphy, DO, MSc
Co-Director NF Clinic
Valley Children's Hospital
Madera, CA

Pediatric Hematology-Oncology, Pediatric Neuro-Oncology

Dr Green-Murphy is a board-certified pediatric hematologist/oncologist and fellowship trained pediatric neuro-oncologist in Central CA. She is a member of Children's Oncology Group and currently serves as a Sub-PI for her institution. Her clinical interests include pediatric neuro-oncology, neurofibromatosis type 1, neurofibromatosis type 2/schwannomatosis syndrome, brain tumor survivorship, cancer predisposition syndromes, evidence-based treatment of children with underlying genetic syndromes, and increasing access to care for rural/underserved patients with cancer predisposition syndromes.

FRIDAY

October 14

SATELLITE SEMINAR 3: **The Latest Update on Metachromatic** **Leukodystrophy: Screening, Diagnosis, and Emerging** **Treatments to Improve Quality of Life of Patients**

Friday, October 14, 12:00 PM – 2:00 PM
Room: 200/205

Pre-registration link: www.cmeoutfitters.com/CNS2022

Speakers

Florian S. Eichler, MD – Moderator
Associate Professor of Neurology
Massachusetts General Hospital
Harvard Medical School
Boston, MA

Laura A. Adang, MD, PhD
Assistant Professor of Child Neurology
Children's Hospital of Philadelphia
Philadelphia, PA

Rachel E. Hickey, MS, LCGC
Genetic Counselor, Care Coordinator of Leukodystrophy
Clinic
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, IL

Grant Source: Supported by an educational grant from
Takeda Pharmaceuticals U.S.A., Inc.

SATELLITE SEMINAR 4: **Ending the Diagnostic Odyssey Genetic** **Diagnosis in Children Affected by Epilepsy**

Friday, October 14
5:00 PM registration
5:30 PM – 7:00 PM educational session
Room: 200/205

Pre-registration link: <https://na.eventscloud.com/website/44418/>

Pre-registration does not guarantee seating. On-site
registration may be available, space permitting.

Speakers

Neil A. Hanchard, MD, PhD
Adjunct Associate Professor
Department of Molecular and Human Genetics
Baylor College of Medicine
Houston, Texas

Ingo Helbig, MD
Assistant Professor of Neurology
Perelman School of Medicine at the University of
Pennsylvania
Philadelphia, Pennsylvania

J. Michael Graglia, MBA, MA
PATIENT ADVOCATE
Co-Founder & Managing Director
SynGAP Research Fund
Palo Alto, California

Lacey Smith, MS, CGC
Genetic Counseling Program Manager
Epilepsy Genomics at Boston Children's Hospital
Boston, Massachusetts*With special guest and parent
advocate Mike Graglia

Grant Source: Supported by an independent
educational grant from GeneDx|Sema4